How Geopolitical Risks Are Reshaping API Supply Chains
API Supply Chains face tariffs, BIOSECURE and EU policy shifts. Here is how concentration, quality, and capacity risks play out, and how to map, score, and act.
Introduction
Picture a procurement head at a mid-sized generics company. Her portfolio looks diversified: twelve products, three finished-dose sites, two continents.
Then a risk review traces the upstream chain. Nine of those twelve products depend on the same key starting materials (KSMs) from the same region.
This is an illustrative scenario, not a specific company. But it captures the shift now underway: geopolitical risk has moved from a footnote in supplier audits to a board-level variable in API supply chain design.
Where the Concentration Really Sits
The picture depends on what you measure. The USP Medicine Supply Map shows India manufacturing the largest share of both essential (29%) and non-essential (38%) APIs worldwide. It also shows China’s share has grown to double digits, from 8% in the prior year.
The deeper exposure sits one step upstream. India’s own pharmaceutical supply chain remains heavily dependent, at 65%, on Chinese imports for critical APIs, KSMs, and intermediates.
Indicator | Figure | Source | So what |
|---|---|---|---|
India’s share of essential APIs manufactured globally | 29% | USP Medicine Supply Map | The finished-API hub is not the whole story |
China’s share of India’s antibiotic imports | 86.1% | NITI Aayog Trade Watch | Antibiotics are the most exposed category |
China’s share of India’s nitrogen heterocyclic imports | 76.4% | NITI Aayog Trade Watch | Intermediates carry hidden dependency |
Essential APIs used in generics | 92% | USP | The medicines patients rely on most run on the thinnest margins |
NITI Aayog attributes this to China’s “scale advantages, integrated chemical manufacturing ecosystem, and cost competitiveness.”
The insight: Concentration is not a failure of any one company. It is the rational result of cost-driven sourcing over decades. That is exactly why it is hard to unwind.
Why Geopolitics Changed the Equation
Three forces are converging: trade policy, national security law, and industrial policy. Each pushes in a slightly different direction, which is what makes planning difficult.
Tariffs: from threat to instrument
On 2 April 2026, a Section 232 proclamation imposed a 100% ad valorem tariff on products listed in Annex I, with targeted carveouts and reduced-rate pathways, for patented pharmaceuticals and APIs.
Crucially, generics, including biosimilars, and their ingredients are not subject to tariffs currently. The proclamation also exempts purchases of generic pharmaceuticals and ingredients for the Strategic API Reserve.
The word “currently” matters. Generic API buyers should plan for scenarios in which that exemption narrows.
National security law: the BIOSECURE Act
A revised BIOSECURE Act was signed into law on December 18, 2025, as Section 851 of the FY2026 NDAA. It restricts US federal procurement and grants involving biotechnology from “biotechnology companies of concern.”
Even companies with no federal contracts feel the effect. Partners, investors, and customers increasingly ask where upstream materials come from.
Industrial policy: the EU Critical Medicines Act
On 11 May 2026, the Council and Parliament reached political agreement on the Critical Medicines Act, now subject to formal approval.
Where dependence on one or a few third countries is high, the Act foresees an obligation for contracting authorities to favour manufacturing in the EU. One MEP framed the trade-off as “money for access and security of supply.”
Policy lever | Region | Status | Practical effect on API sourcing |
|---|---|---|---|
Section 232 tariffs | US | Proclaimed April 2026 | Higher cost for patented products unless onshoring or pricing deals exist |
Generic and Strategic API Reserve exemption | US | In force “at this time” | Short-term relief, long-term uncertainty |
BIOSECURE Act | US | Law since December 2025 | Supplier screening and documentation demands |
Critical Medicines Act | EU | Political agreement, formal approval pending | Procurement favors diversification and EU manufacturing |
Tariffs are only one of the three forces reshaping sourcing. See exactly what the Section 232 proclamation covers, and what it leaves out.
Read: The Section 232 Pharmaceutical Tariff, Read From The Proclamation
The Hidden Cost: Quality Does Not Move for Free
Re-sourcing sounds like a procurement exercise. For active pharmaceutical ingredients, it is a quality exercise first.
A new supplier means new process knowledge, new impurity profiles, and new inspection history. History offers a warning: in 2018, the probable carcinogen NDMA was found in valsartan APIs from a Chinese manufacturer after an undisclosed process change.
The lesson is not “avoid any region.” It is that single-source dependency and weak process transparency amplify each other.
What this means for your quality system:
Supplier qualification must cover process-change notification, not just certificates
Impurity risk assessments (including nitrosamines) need refreshing for each new route
Tech transfer and comparability data can become the new critical path
Contamination control and microbiological risk need review whenever a site or supplier changes
Capacity Is the Other Constraint
Shifting volume only works if someone can absorb it. In high-demand segments, CDMOs unanimously confirmed that capacity for large-scale biologics and aseptic fill-finish remains insufficient.
Inputs can bottleneck too. Panelists at a 2025 industry conference flagged a worldwide shortage of acetonitrile, an indispensable pharmaceutical solvent, as GLP-1 demand and tariff uncertainty collided.
The insight: Diversification plans fail when every company chases the same alternative suppliers at once. Early movers secure capacity, and late movers inherit the risk.
Shifting volume only works if someone can absorb it. See why all the announced fill-finish capacity is still not closing the gap.
Read: Every Company Announced Fill-Finish Capacity: Still Scarce?
Four Strategic Responses Taking Shape
Strategy | What it means | Main trade-off |
|---|---|---|
Dual sourcing | Qualify a second API source for critical products | Qualification cost and regulatory filings |
China+1 | Add capacity in India, Southeast Asia, or elsewhere | Upstream KSM dependency often remains |
Onshoring or nearshoring | Build or contract capacity in the US or EU | Higher cost, longer lead time, talent constraints |
Strategic inventory | Hold buffer stock of critical APIs or KSMs | Working capital and shelf-life risk |
A common mistake is treating “China+1” as complete. If the new site imports its starting materials from the same region, the dependency has moved, not disappeared. Mapping must go to the KSM level.
A Risk Lens That Works: Map, Score, Act
Map every critical API to its KSMs, intermediates, and manufacturing sites
Score each node on concentration, regulatory exposure, tariff exposure, and quality history
Act with a tiered plan: dual-source the highest-risk items first, buffer the rest
The most useful single metric is often supplier concentration: the share of volume coming from your top three sources, and from one country, per product.
Frequently Asked Questions
What is an API supply chain?
It is the network that turns raw materials and KSMs into active pharmaceutical ingredients, then into finished medicines. Each step can sit in a different country.
Which countries dominate API manufacturing?
India and China are central. USP data shows India with the largest share of essential API manufacturing, while China remains critical upstream in KSMs and intermediates.
How do tariffs affect API sourcing?
Section 232 tariffs target patented pharmaceuticals and their APIs, with carveouts. Generics and Strategic API Reserve purchases are currently exempt, but policy may change.
What is the BIOSECURE Act?
It is a US law, signed in December 2025, that restricts federal procurement and grants involving certain “biotechnology companies of concern.” It influences supplier due diligence across the sector.
What is the best way to reduce API supply risk?
Combine mapping to KSM level, dual sourcing for critical products, and targeted buffer stock. No single tactic is enough.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from the Knowledge Hub
All articles →
Pharmaceutical Regulatory Affairs: Challenges, Innovations, and Global Harmonization
Cold Chain Logistics in Pharma: Building Resilient Supply Chains
Discussion